BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/14/2019 9:34:50 AM | Browse: 841 | Download: 1160
 |
Received |
|
2019-03-14 00:35 |
|
Peer-Review Started |
|
2019-03-14 00:45 |
|
To Make the First Decision |
|
2019-04-08 01:12 |
|
Return for Revision |
|
2019-04-08 07:17 |
|
Revised |
|
2019-04-13 14:54 |
|
Second Decision |
|
2019-04-28 09:55 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2019-04-29 10:17 |
|
Articles in Press |
|
2019-04-29 10:17 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2019-05-20 17:00 |
|
Typeset the Manuscript |
|
2019-06-13 08:32 |
|
Publish the Manuscript Online |
|
2019-06-14 09:34 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Shun-Zhen Zheng, Ping Sun, Jian-Ping Wang, Yong Liu, Wei Gong and Jun Liu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
81302124 |
| Shandong Key R&D Program |
2017GSF218038 |
| Shandong Provincial Natural Science Foundation |
ZR2014HP065 |
|
| Corresponding Author |
Jun Liu, MD, Professor, Surgeon, Department of Liver Transplantation and Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong University, No. 324 Jingwu Road, Jinan 250021, Shandong Province, China. dr_liujun1967@126.com |
| Key Words |
MiR-34a; Doxorubicin; Hepatocellular carcinoma; HepG2 cells; Growth inhibition |
| Core Tip |
Hepatocellular carcinoma (HCC) is the third leading cause of death from malignant tumors worldwide. The prognosis remains poor and the overall efficacy is still unsatisfactory. Chemotherapy resistance is the most important reason for the poor outcome of HCC. We found that upregulation of miR-34a can increase the chemosensitivity of HCC cells to doxorubicin. MiR-34a may enhance the inhibitory effect of doxorubicin by downregulating multidrug resistance protein 1/P glycoprotein and AXL, which may be related to expression of p53. |
| Publish Date |
2019-06-14 09:34 |
| Citation |
Zheng SZ, Sun P, Wang JP, Liu Y, Gong W, Liu J. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells. World J Gastroenterol 2019; 25(22): 2752-2762 |
| URL |
https://www.wjgnet.com/1007-9327/full/v25/i22/2752.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v25.i22.2752 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
